mobile logo

Expanding from
Single Cancer Tests
to a Multi-Cancer Screen

IONIQ Development Pipeline

ProLung Test for lung cancer - FDA Breakthrough Device and multiple trials completed
Breast Cancer Test - Feasibility results already published by IEEE
LUNA 3 next-gen, portable platform
Multi-Cancer Screen

The ProLung Test

Lung cancer is leading cause of cancer-related deaths worldwide

Shifting diagnosis to earliest stages of the disease can improve 5 year survivability from 17% to 80%

IONIQ ProLung Test can reduce false positives from today's low dose CT standard of care by 86%

IONIQ is 3-5x more accurate in early-stages than liquid biopsies or blood tests

  • Undergone 7 clinical trials across 3 continents
  • Over 1,400 subjects tested as part of our clinical trials
  • Designed to empower physicians to accelerate their diagnosis
  • Designated ‘Breakthrough Device‘ by US FDA for its life-enhancing potential
  • FDA currently reviewing de novo application for marketing clearance in USA 
  • Not available for sale in the USA

IONIQ Breast Test

Breast cancer is the leading cause of cancer in women

47% of women globally have dense breasts, which are challenging for mammography

IONIQ feasibility data demonstrated efficacy in extremely dense breasts

Ability to distinguish between malignant and benign breast lesions

  • Bench work started 2019
  • Feasibility study started January 2020
  • Clinical validation trial to follow completion of feasibility studies
  • Not available for sale in the USA

"Skin Electrical Resistance as a Diagnostic and Therapeutic Biomarker of Breast Cancer Measuring Lymphatic Regions" (IEEE)

Scientific manuscript conclusions:

  • Shows promise as breast cancer diagnostic – significant differences between malignant and benign breast lesions
  • Post-therapeutic monitoring – patients had higher normalized bioimpedance readings after treatment versus pre-treatment
  • No radiation – well suited to frequent follow-up’s or where mammography is contraindicated
  • Initial feasibility clinical trial results published by IEEE in 2021

LUNA 3

Next-gen, portable platform enabling our Multi-Cancer Screen

Moving from the hospital and clinic to your home

  • Enabling Multi-Cancer Screen
  • Cloud-based and AI-powered
  • Reduced cost
  • Modernized
  • Portable

We aim to be the first FDA cleared
Multi-Cancer Screen

Screening can save lives and money by detecting cancer at its earliest most treatable stages when the 5yr survival approaches 90% versus just 10% in later stages

Our lung cancer and breast cancer tests are foundational on our quest to developing a Multi-Cancer Screen.

We are well positioned to develop a multi-cancer screen by leveraging our lung test, breast test, proprietary technology, substantial EIA biompedance database, and our deep clinical experience.

Not available for sale in the USA.